Capricor Therapeutics is trading 9.18% up now at $7.73 as biotechnology shares rally broadly.
- Positive sector momentum appears to be supporting the move.
- Investors continue positioning ahead of the FDA’s August 22 PDUFA decision for deramiocel.
- No new company-specific announcement clearly explains the August 19 advance; a securities-fraud class-action announcement was reported, but it does not provide a bullish catalyst.